Follicum AB (“Follicum”) today announces that Professor Jan Nilsson´s research group at the Clinical Research Center, Lund University has been granted 400 000 Danish crowns from the Novo Nordisk Foundation to carry out pre-clinical diabetes studies with Follicum’s peptides. The aim of the pre-clinical experiments is to study the effects and mechanisms of action of Follicum’s patented peptides.
The Novo Nordisk Foundation primarily allocates funding to research within fields such as biomedicine, biotechology and general medicine to public research organsiations. The 400 000 Danish crowns has been allocated to an application entitled “Identification of osteopontin-related peptides stimulating insulin secretion”.
In the spring of 2017, Follicum announced that the company had widened its area of research and submitted a patent application regarding peptides that have shown a positive effect on the release of insulin. The effects of these substances were discovered during pre-clinical studies in cooperation with Professor Jan Nilsson.
Follicum has long been a part of a large Diabetes project, financed by the Swedish Foundation for Strategic Research, which is being carried out in cooperation with Lund University about individually adapted medicines in diabetes. In addition to Follicum, Novo Nordisk, Johnson & Johnson Innovation, Pfizer, Probi, CardioVax and Skåne University Hospital in Malmö are part of the project.
CEO Jan Alenfall’s comments
– That Follicum’s diabetes project is now, over and above previously acquired funding from the Swedish Foundation for Strategic Research, has also has recieved funding from the Novo Nordisk Foundation, is yet another confirmation of the fact that our diabetes project is most interesting. We are very happy that the research group at CRC has acquired this grant, since this means that our work on the diabetes project can accelerate. Follicum’s main focus continues to be the development of effective drugs for the regulation of hair growth.
For further information, please contact:
Jan Alenfall – CEO, Follicum AB
Telephone: 046 – 19 21 97
Mikael Theander, Communications & PR
This information is information that Follicum is obliged to make public according to the EU Market Abuse Regulation. The information was provided through the agency of the contact persons above, for publication on the 5th September, 2017.
About Follicum AB
Follicum was founded in 2011 by two researchers in Lund, Anna Hultgårdh and Pontus Dunér, based on research around a human protein, osteopontin. Among other things, this protein is considered to be involved in the growth of bone tissue. Follicum has isolated a part of this protein and partially modified its amino acid sequence, which generated Follicum’s drug candidate FOL-005. In early studies, FOL-005 showed an ability to both stimulate and inhibit hair growth. During 2016/2017, the company conducted its first clinical phase I/IIa study. Follicum is based in Lund and was listed on AktieTorget in 2014.
About the Novo Nordisk Foundation
The Novo Nordisk Foundation is an independent Danish foundation with corporate interests.The objective of the Novo Nordisk Foundation is twofold: To provide a stable basis for the commercial and research activities conducted by the companies within the Novo Group and to support scientific and humanitarian purposes.
To contribute significantly to research and development that improves the health and welfare of people.
The Foundation uses its independence, flexibility and long-term perspective to promote world-class research. In this way the Foundation contributes to developing solutions that address the pressing challenges of the future – to benefit both individuals and society as a whole.
The Clinical Research Centre (CRC) is the Medical faculty’s central point for medicinal education, research and health care in for Malmö hospitals and clinics. CRC is a part of Lund Univerity, a world class university which understands, explains and improves our world and human needs. The university is ranked as one of theglobal top 100. Around 50 research groups are active at CRC, 520 researchers, postgraduates and technical/administrative staff as well as 560 undergraduate students in a state-of-the-art research environment.